Caprock Group’s Corcept Therapeutics CORT Stock Holding History

Caprock Group’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-10,384	Closed	-$214K	–	461
2017 Q4	$214K	Buy	+10,384	New	+$188K	0.04%	407

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Caprock Group's CORT Position: Q1 2018 in Review

Caprock Group sold out of Corcept Therapeutics (CORT) in Q1 2018, closing a stake of 10,384 shares — an estimated $214K sold.

Caprock Group first reported a position in CORT in Q4 2017 and held it in 1 quarter. The position peaked at $214K in Q4 2017. 212 funds tracked by Wall St. Rank hold CORT as of Q1 2018.

Caprock Group reported no remaining Corcept Therapeutics position as of Q1 2018 after selling out during the quarter.
Caprock Group sold 10,384 Corcept Therapeutics shares in Q1 2018, an estimated $214K.
Caprock Group first reported a position in Corcept Therapeutics in Q4 2017 and held it in 1 quarter.
Caprock Group's Corcept Therapeutics position peaked at $214K in Q4 2017.
212 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2018.

Based on Caprock Group's 13F filing for Q1 2018, filed 23 Apr 2018.